Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MIFEPREX
- Understanding GWI: Integrative Modeling
- TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
- Advance Provision of Medication Abortion
- Blocking Mifepristone Action With Progesterone
- Medication Abortion Via Pharmacy Dispensing
- Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
- A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks
- A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion
- Non-surgical Alternatives to Treatment of Failed Medical Abortion
- Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks
- Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
- Medication Enhanced Rapid Therapy
- Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Comparative Effectiveness of Pregnancy Failure Management Regimens
- Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
- Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
- Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion
- Cervical Preparation Before Dilation and Evacuation
- Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders
- Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
- Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
- Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks
- Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
- The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors
- Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
Clinical trials list
click for details